KMM Group, a vertically integrated precision contract manufacturer for the medical device industry, announced the completion of an investment from RS2 Healthcare Partners, a Boston-based private equity firm. Financial terms were not disclosed.
Alongside the investment, KMM appointed industry veteran J. Mark King as President and Chief Executive Officer. King previously served as President and CEO of Tegra Medical, a former RS2 Healthcare Partners portfolio company, and before that led Clinical Innovations, a women’s health medical device company, and held leadership roles at Baxter Healthcare, Cardinal Health, and Johnson & Johnson. Co-founder John Shegda will serve as Chief Technology Officer overseeing engineering and technology strategy, while co-founder Eric Wilhelm has been named Executive Vice President of Business Transformation and Organizational Capability, overseeing operational excellence and scalable growth.
KEY QUOTES:
“KMM has earned customers’ trust by solving complex manufacturing challenges that many others simply cannot do. I have a long history of working with the principals at RS2 Healthcare Partners as well as serving as an advisor to KMM. With this investment, I look forward to partnering with RS2, John, Eric and the rest of the KMM team to expand the Company’s capabilities and further strengthen its position as a premier contract manufacturer for medtech and other end markets.”
J. Mark King, President and CEO, KMM Group
“KMM is an exceptional company, with an excellent reputation in the marketplace, highly specialized capabilities, a blue chip customer base, and an extremely dedicated group of employees. We are thrilled to partner with John, Eric, and Mark for the Company’s next chapter.”
Craig Stern, Co-Managing Partner, RS2 Healthcare Partners
